Viking Therapeutics EBIT

Viking Therapeutics (VKTX) currently reports a EBIT of $-500M as of March 2026. That compares with $-170M in the prior-year period — down 191.2% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Viking Therapeutics's EBIT history and peer comparisons.

Viking Therapeutics's EBIT decreased from $-170M to $-500M — a 191.2% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Viking Therapeutics's EBIT of $-500M is lower than the Healthcare sector average of $23B. That is roughly 102.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Viking Therapeutics reported $-500M in EBIT as of March 2026. That compares with $-170M in the prior-year period — down 191.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-500M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Viking Therapeutics, and consider following VKTX for alerts when major investors trade the stock.